• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Phase III trials begin for steroid compound

Article

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Sirion acquired the drug last year through an exclusive licensing agreement with Senju Pharmaceutical Co. Ltd., Japan. The deal gave Sirion U.S. rights to develop and market a topical ophthalmic emulsion containing difluprednate for the treatment of inflammatory eye diseases.

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.